QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 us-stocks-likely-to-open-higher-as-wall-street-watches-trump-tariff-talks-march-april-may-tend-to-be-solid-months-in-post-election-years-says-expert

US. stock futures rose on Monday following Friday's advances. Futures of all fourth benchmark indices rose in premarket tra...

 syros-announces-voluntary-delisting-from-nasdaq-and-sec-deregistration-delisting-is-expected-to-become-effective-on-or-about-march-20-2025

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the "Company") today announced that its Board of Directors (the "Board&#...

Core News & Articles

On November 13, 2024, Syros Pharmaceuticals, Inc. (the "Company") gave notice to QIAGEN Manchester Limited ("QIAGEN...

 syros-pharmaceuticals-stock-sinks-as-pivotal-blood-cancer-trial-flunks-triggers-loan-default

Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints...

 td-cowen-downgrades-syros-pharmaceuticals-to-hold

TD Cowen analyst Phil Nadeau downgrades Syros Pharmaceuticals (NASDAQ:SYRS) from Buy to Hold.

 hc-wainwright--co-downgrades-syros-pharmaceuticals-to-neutral-lowers-price-target-to-1

HC Wainwright & Co. analyst Andrew Fein downgrades Syros Pharmaceuticals (NASDAQ:SYRS) from Buy to Neutral and lowers th...

 jmp-securities-downgrades-syros-pharmaceuticals-to-market-perform

JMP Securities analyst Jason Butler downgrades Syros Pharmaceuticals (NASDAQ:SYRS) from Market Outperform to Market Perform.

 brookline-capital-downgrades-syros-pharmaceuticals-to-hold

Brookline Capital analyst Leah Rush downgrades Syros Pharmaceuticals (NASDAQ:SYRS) from Buy to Hold.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION